0000000000380365

AUTHOR

Federico Colombo

0000-0003-4480-3481

showing 5 related works from this author

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

2019

All authors: Andrea Cossarizza Hyun‐Dong Chang Andreas Radbruch Andreas Acs Dieter Adam Sabine Adam‐Klages William W. Agace Nima Aghaeepour Mübeccel Akdis Matthieu Allez Larissa Nogueira Almeida Giorgia Alvisi Graham Anderson Immanuel Andrä Francesco Annunziato Achille Anselmo Petra Bacher Cosima T. Baldari Sudipto Bari Vincenzo Barnaba Joana Barros‐Martins Luca Battistini Wolfgang Bauer Sabine Baumgart Nicole Baumgarth Dirk Baumjohann Bianka Baying Mary Bebawy Burkhard Becher Wolfgang Beisker Vladimir Benes Rudi Beyaert Alfonso Blanco Dominic A. Boardman Christian Bogdan Jessica G. Borger Giovanna Borsellino Philip E. Boulais Jolene A. Bradford Dirk Brenner Ryan R. Brinkman Anna E. S. Broo…

0301 basic medicineConsensusImmunologyConsensuCell SeparationBiologyArticleFlow cytometry03 medical and health sciences0302 clinical medicineGuidelines ; Immunology ; Flow cytometryAllergy and ImmunologymedicineCell separationImmunology and AllergyHumansguidelines; flow cytometry; immunologymedicine.diagnostic_testBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Cell sortingFlow CytometryCell selectionData science3. Good health030104 developmental biologyPhenotypeAllergy and Immunology; Cell Separation; Consensus; Flow Cytometry; Humans; Phenotype[SDV.IMM]Life Sciences [q-bio]/ImmunologyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.030215 immunologyHumanEuropean journal of immunology
researchProduct

OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis

2016

Background Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting joints due to the persistent synovial tissue inflammation. RA treatment has dramatically evolved in the last 20 years due to the production of biological Disease Modifying Antirheumatic Drugs (bDMARDs). However, side effects and the high costs of biological drugs are holding back their widespread usage. Moreover, some patients fail to respond to bDMARDs, for all of these reasons, DMARDs remains the main desired strategy for the treatment of RA, and Methotrexate (MTX) is still the “anchor” drug to treat RA. A successful treatment depends also on the early diagnosis, treating patients as soon as possible …

Drugrheumatoid arthritisInflammatory arthritismedia_common.quotation_subjectImmunologyArthritisInflammationPharmacologyGeneral Biochemistry Genetics and Molecular BiologymethotrexateRheumatologyIn vivomedicineImmunology and Allergyrheumatoid arthritis; nanoparticles; collagen induced arthritis; methotrexatemedia_commonbusiness.industrynanoparticleTherapeutic effectrheumatoid arthritimedicine.diseasecollagen induced arthritiscollagen induced arthritiRheumatoid arthritisImmunologyMethotrexatenanoparticlesmedicine.symptombusinessmedicine.drug
researchProduct

NKp46-expressing human gut-resident intraepithelial Vδ1 T cell subpopulation exhibits high antitumor activity against colorectal cancer

2019

γδ T cells account for a large fraction of human intestinal intraepithelial lymphocytes (IELs) endowed with potent anti-tumor activities. However, little is known about their origin, phenotype and clinical relevance in colorectal cancer (CRC). To determine γδ IEL gut-specificity, homing and functions, γδ T cells were purified from human healthy blood, lymph nodes, liver, skin, intestine either disease-free or affected by CRC or generated from thymic precursors. The constitutive expression of NKp46 specifically identifies a new subset of cytotoxic Vδ1 T cells representing the largest fraction of gut-resident IELs. The ontogeny and gut-tropism of NKp46pos/Vδ1 IELs depends both on distinctive …

0301 basic medicineMaleColorectal cancerImmunotherapy AdoptiveMice0302 clinical medicineSex Hormone-Binding GlobulinCytotoxic T cellAntigens LyIntestinal MucosaIntraepithelial LymphocytesInnate immunityAged 80 and overGastroenterologyAge FactorsReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle AgedPhenotypemedicine.anatomical_structure030220 oncology & carcinogenesisDisease ProgressionFemaleColorectal NeoplasmsResearch ArticleAdultColonT cellImmunologyT cellsBiologydigestive systemColorectal cancer; Gastroenterology; Immunology; Innate immunity; T cells03 medical and health sciencesYoung AdultIleummedicineAnimalsHumansAgedNeoplasm StagingTumor microenvironmentInnate immune systemNatural Cytotoxicity Triggering Receptor 1medicine.diseaseColorectal cancer030104 developmental biologyCancer researchIntraepithelial lymphocyteHoming (hematopoietic)T-Lymphocytes Cytotoxic
researchProduct

Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis

2019

Abstract Despite the advances in the treatment of rheumatoid arthritis (RA) achieved in the last few years, several patients are diagnosed late, do not respond to or have to stop therapy because of inefficacy and/or toxicity, leaving still a huge unmet need. Tissue-specific strategies have the potential to address some of these issues. The aim of the study is the development of a safe nanotechnology approach for tissue-specific delivery of drugs and diagnostic probes. CD34 + endothelial precursors were addressed in inflamed synovium using targeted biodegradable nanoparticles (tBNPs). These nanostructures were made of poly-lactic acid, poly-caprolactone, and PEG and then coated with a synovi…

musculoskeletal diseases0301 basic medicineBiodistributionCD34; +; cells; Neoangiogenesis; Rheumatoid arthritis; Targeted nanoparticles; Targeted therapymedicine.medical_treatmentTargeted nanoparticlesImmunologyArthritisInflammation+Targeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinemedicineImmunology and AllergyProgenitor cellRheumatoid arthritisRheumatoid arthritiTargeted nanoparticleNeoangiogenesis030203 arthritis & rheumatologybusiness.industrycellmedicine.diseaseNeoangiogenesi030104 developmental biologyRheumatoid arthritisToxicityCancer researchcellsMethotrexateCD34medicine.symptombusinessmedicine.drug
researchProduct

FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis

2016

Background TNF-α neutralizing molecules represent one of the most efficient therapeutic approaches to control inflammation in rheumatoid arthritis (RA). The widespread distribution in the body induces the inhibition of TNF-α in all the tissues, requesting the use of high dose of this expensive drug. Another problem that has not yet been solved in the management of RA patients is how to reduce and possibly avoid the side effects, particularly the increased risk of common and opportunistic infections, which may be associated with long-term administration of these therapeutic drugs. Objectives The aim of the present investigation was to show that a recombinant protein obtained by fusing a syno…

rheumatoid arthritisPathologymedicine.medical_specialtyImmunologyArthritisInflammationImmunofluorescenceGeneral Biochemistry Genetics and Molecular BiologyRheumatologyIn vivoAdalimumabmedicineImmunology and AllergyNeutralizing antibodyantigen induced arthritismedicine.diagnostic_testbiologybusiness.industrytarget therapyantigen induced arthritirheumatoid arthritimedicine.diseaseRheumatoid arthritisImmunologyrheumatoid arthritis; antigen induced arthritis; target therapy; immunotherapybiology.proteinTumor necrosis factor alphaimmunotherapymedicine.symptombusinessmedicine.drug
researchProduct